Recent Progress in Repositioning Alzheimer'S Disease Drugs Based on a Multitarget Strategy

References

• Jellinger KA . Alzheimer 100-Highlights in the history of Alzheimer research. J. Neural. Transm.113, 1603–1623 (2006).
   PubMed Web of Science ®Google Scholar
• Bartus RT , DeanRL, BeerB, LippaAS. The cholinergic hypothesis of geriatric memory dysfunction. Science217, 408–417 (1982).
   PubMed Web of Science ®Google Scholar
• Giacobini E . Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In : The Brain Cholinergic System in Health and Disease. GiacobiniE, PepeuG ( Eds). Informa Healthcare, Oxon, UK, 235–264 (2006).
   Google Scholar
• Henry W , QuerfurthHW, LaFerlaFM. Alzheimer's disease. N. Engl. J. Med.362, 329–344 (2010).
   PubMed Web of Science ®Google Scholar
• Medeiros R , ChabrierMA, LaFerlaFM. Elucidating the triggers, progression, and effects of Alzheimer's disease. J. Alzheimers Dis.33, S195–S210 (2013).
   PubMed Web of Science ®Google Scholar
• Cummings JL . Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement.5, 406–418 (2009).
   PubMed Web of Science ®Google Scholar
• Small G , BullockR. Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement.7, 177–184 (2011).
   PubMed Web of Science ®Google Scholar
• Parsons CG , StofflerA. DanyszW. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology53, 699–723 (2007).
   PubMed Web of Science ®Google Scholar
• Tan CC , YuJT, WangHFet al. Efficacy and safety of donepezil, galanthamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimer's Dis.41, 615–631 (2014).
   PubMed Web of Science ®Google Scholar
• Hansen RA , GartlehnerG, WebbAP, MorganLC, MooreCG, JonasDE. Efficacy and safety of donepezil, galanthamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin. Interv. Aging3, 211–225 (2008).
   PubMed Web of Science ®Google Scholar
• Crismon ML . Tacrine: first drug approved for Alzheimer's disease. Ann. Pharmacother.28, 744–751 (1994).
   PubMed Web of Science ®Google Scholar
• Bryson HM , BenfieldP. Donepezil. Drugs Aging10, 234–239 (1997).
   PubMed Web of Science ®Google Scholar
• Polinsky RJ . Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther.20, 634–647 (1998).
   PubMed Web of Science ®Google Scholar
• Tang XC , DeSarnoP, SugayaK, GiacobiniE. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J. Neurosci. Res.24, 276–285 (1989).
   PubMed Web of Science ®Google Scholar
• Ma X , TanC, ZhuDet al. Huperzine A from Huperzia species; an ethnopharmacological review. J. Ethnopharmacol.113, 15–34 (2007).
   PubMed Web of Science ®Google Scholar
• Scott LJ , GoaKL. Galanthamine: a review of its use in Alzheimer's disease. Drugs60, 1095–1122 (2000).
   PubMed Web of Science ®Google Scholar
• Brown D , Superti-FurgaG. Rediscovering the sweet spot in drug discovery. Drug Discov. Today8, 1067–1077 (2003).
   PubMed Web of Science ®Google Scholar
• Overington JP , Al-LazikaniB, HopkinsAL. How many drug targets are there?Nat. Rev. Drug. Discov.5, 993–996 (2006).
   PubMed Web of Science ®Google Scholar
• Szuromi P , VinsonV, MarshalE. Rethinking drug discovery. Science303, 1795 (2004).
   Web of Science ®Google Scholar
• Wischik CM , HarringtonCR, StoreyJM. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem. Pharmacol.88, 529–539 (2014).
   PubMed Web of Science ®Google Scholar
• Doig AJ , DerreumauxP. Inhibition of protein aggregation and amyloid formation by small molecules. Curr. Opin Struct. Biol.30, 50–56 (2015).
   PubMed Web of Science ®Google Scholar
• Ladner CJ , LeeJM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J. Neuropath. Exp. Neur.57, 719–731 (1998).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ . Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl Acad. Sci. USA98, 11039–11041 (2001).
   PubMed Web of Science ®Google Scholar
• Hardy J , SelkoeDJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science297, 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ . Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev.81, 741–766 (2001).
   PubMed Web of Science ®Google Scholar
• Eanes ED , GlennerGG. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem.16, 673–677 (1968).
   PubMed Web of Science ®Google Scholar
• Hoyer W , GronwallC, JonssonA, StahlS, HardT. Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation. Proc. Natl Acad. Sci. USA105, 5099–5104 (2008).
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE , BieschkeJ, BoeddrichAet al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol.15, 558–566 (2008).
   PubMed Web of Science ®Google Scholar
• Bieschke J , RussJ, FriedrichRPet al. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc. Natl Acad. Sci. USA107, 7710–7715 (2010).
   PubMed Web of Science ®Google Scholar
• Lau LF , SchachterJB, SeymourPA, SannerMA. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr. Top. Med. Chem.2, 395–415 (2002).
   PubMedGoogle Scholar
• Dickey CA , KamalA, LundgrenKet al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest.117, 648–658 (2007).
   PubMed Web of Science ®Google Scholar
• Silva T , TeixeiraJ, RemiaoF, BorgesF. Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways. Angew. Chem. Int. Ed. Engl.52, 1110–1121 (2013).
   PubMed Web of Science ®Google Scholar
• Ayton S , LeiP, BushAI. Metallostasis in Alzheimer's disease. Free Radical Biol. Med.62, 76–89 (2013).
   PubMed Web of Science ®Google Scholar
• Scott LE , OrvigC. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem. Rev.109, 4885–4910 (2009).
   PubMed Web of Science ®Google Scholar
• Curtain CC , AliF, VolitakisIet al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem.276, 20466–20473 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu X , SuB, WangX, SmithMA, PerryG. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci.64, 2202–2210 (2007).
   PubMed Web of Science ®Google Scholar
• Santos MA , ChandK, ChavesS. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease. Coord. Chem. Rev. doi:10.1016/j.ccr.2016.04.013 (2016) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Medina-Franco JL , GiulianottiMA, WelmakerGS, HoughtenRA. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov. Today18, 495–501 (2013).
   PubMed Web of Science ®Google Scholar
• Morphy R , RankovicZ. Designed multiple ligands. an emerging drug discovery paradigm. J. Med. Chem.48, 6523–6543 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmerman GR , LeharJ, KeithCT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today12, 34–42 (2007).
   PubMed Web of Science ®Google Scholar
• Youdim MB , BuccafuscoJJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci.26, 27–35 (2005).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML , CavalliA, BergaminiCet al. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem.52, 7883–7886 (2009).
   PubMed Web of Science ®Google Scholar
• Leon R , GarciaAG, Marco-ContellesJ. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev.33, 139–189 (2013).
   PubMed Web of Science ®Google Scholar
• Romero A , CacabelosR, Oset-GasqueMJ, SamadiA, Marco-contellesJ. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett.23, 1916–1922 (2013).
   PubMed Web of Science ®Google Scholar
• Lee S , ZhengX, KrishnamoorthyJet al. Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer's disease. J. Am. Chem. Soc.136, 299–310 (2014).
   PubMed Web of Science ®Google Scholar
• Trippier PC , LabbyKJ, HawkerDD, MatakaJ, SilvermanRB. Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J. Am. Chem. Soc.56, 3121–3147 (2013).
   Google Scholar
• Rochais C , LecouteyC, GavenFet al. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J. Med. Chem.58, 3172–3187 (2015).
   PubMed Web of Science ®Google Scholar
• De los Rios C . Cholinesterase inhibitors: a patent review (2007–2011). Expert Opin. Ther. Pat.22, 853–869 (2012).
   PubMed Web of Science ®Google Scholar
• Pohanca M . Acetylcholinesterase inhibitors: a patent review (2008–present). Expert Opin. Ther. Pat.22, 871–886 (2012).
   PubMed Web of Science ®Google Scholar
• Anand P , SinghB. A review on cholinesterase inhibitors for Alzheimer's disease. Arch. Pharm. Res.36, 375–399 (2013).
   PubMed Web of Science ®Google Scholar
• Giacobini E , GoldG. Alzheimer disease therapy – moving from amyloid-β to tau. Nat. Rev. Neurol.9, 677–686 (2013).
   PubMed Web of Science ®Google Scholar
• Carreiras MC , MendesE, PerryMJ, FranciscoAP, Marco-ContellesJ. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem.13, 1745–1770 (2013).
   PubMed Web of Science ®Google Scholar
• Minarini A , MilelliA, SimoniEet al. Multifunctional tacrine derivatives in Alzheimer's disease. Curr. Top. Med. Chem.213, 1771–1786 (2013).
   Google Scholar
• Agis-Torres A , SolhuberM, FernandezM, Sanchez-MonteroJM. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease. Curr. Neuropharmacol.12, 2–36 (2014).
   PubMed Web of Science ®Google Scholar
• Guzior N , WieckowskaA, PanekD, MalawskaB. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr. Med. Chem.22 (3), 373–404 (2015).
   PubMed Web of Science ®Google Scholar
• Pisani L , CattoM, LeonettiFet al. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. Curr. Med. Chem.18, 4568–4587 (2011).
   PubMed Web of Science ®Google Scholar
• Ahmad I , NirogiR. 5-HT4 receptor agonists for the treatment of Alzheimer's disease. Neurosci. Med.2, 87–92 (2011).
   Google Scholar
• Koch HJ , HaasS, JurgensT. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease. Curr. Med. Chem.12, 2915–2921 (2005).
   PubMed Web of Science ®Google Scholar
• Inestrosa NC , AlvarezA, PérezCAet al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron16, 881–891 (1996).
   PubMed Web of Science ®Google Scholar
• Watkins PB , ZimmermanHJ, KnappMJ, GraconSI, LewisKW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA271, 992–998 (1994).
   PubMed Web of Science ®Google Scholar
• Xing S-H , ZhuC-X, ZhangR. AnL. Huperzine A in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evid. Based Complement. Alternat. Med. 2014, 363985 (2014).
   PubMed Web of Science ®Google Scholar
• Ma X , GangDR. The lycopodium alkaloids. Nat. Prod. Rep.21, 752–772 (2004).
   PubMed Web of Science ®Google Scholar
• Munoz-Muriedas J , LopezJM, OrozcoM, LuqueFJ. Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease. Curr. Pharm. Des.10, 3131–3140 (2004).
   PubMed Web of Science ®Google Scholar
• Tang H , ZhaoL-Z, ZhaoH-Tet al. Hybrids of oxoisoaporphine–tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors. Europ. J. Med. Chem.46, 4970–4979 (2011).
   PubMed Web of Science ®Google Scholar
• Chen Y , SunJ, PengS, LiaoH, ZhangY, LehmannJ. Tacrine–flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease. Arch. Pharm. Chem. Life Sci.346, 865–871 (2013).
   PubMed Web of Science ®Google Scholar
• Luo W , LiY-P, HeYet al. Design, synthesis and evaluation of novel tacrine–multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation. Bioorg. Med. Chem.19, 763–770 (2011).
   PubMed Web of Science ®Google Scholar
• Huang L , SuT, ShanWet al. Inhibition of cholinesterase activity and amyloid aggregation by berberine–phenyl–benzoheterocyclic and tacrine–phenylbenzoheterocyclic hybrids. Bioorg. Med. Chem.20, 3038–3048 (2012).
   PubMed Web of Science ®Google Scholar
• Bajda M , JonczykJ, MalawskaBet al. Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Bioorg. Med. Chem.23, 5610–5618 (2015).
   PubMed Web of Science ®Google Scholar
• Shulman RG , RothmanDL, BeharKL, HyderF. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosc.27, 489–495 (2004).
   PubMed Web of Science ®Google Scholar
• Li F , CalingasanNY, YuFet al. Increased plaque burden in brains of APP mutante MnSOD heterozygous knockout mice. J. Neurochem.89, 1308–1312 (2004).
   PubMed Web of Science ®Google Scholar
• Melov S , AdlardPA, MortenKet al. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE2, e536 (2007).
   PubMed Web of Science ®Google Scholar
• Sompol P , IttaratW, TangpongJet al. A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience153, 120–130 (2008).
   PubMed Web of Science ®Google Scholar
• Schewe T . Molecular actions of Ebselen – an antiinflammatory antioxidant. Gen. Pharmacol.26, 1153–1169 (1995).
   PubMedGoogle Scholar
• Mao F , ChenJ, ZhouQ, LuoZ, HuangL, LiX. Novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. Bioorg. Med. Chem. Let.23, 6737–6742 (2013).
   PubMed Web of Science ®Google Scholar
• Joo Y , KimH-S, WooR-Set al. Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol. Pharmacol.69, 76–84 (2006).
   PubMed Web of Science ®Google Scholar
• Bornstein JJ , EckroatTJ, HoughtonJL, JoneCK, GreencKD, Garneau-TsodikovaS. Tacrine–mefenamic acid hybrids for inhibition of acetylcholinesterase. Med. Chem. Commun.2, 406–412 (2011).
   Google Scholar
• Bar-Am O , AmitT, WeinrebO, YoudimMBH, MandelS. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid protein precursor: involvement of MAPK and PKC activation. J. Alzheimer's Dis.21, 361–371 (2010).
   PubMed Web of Science ®Google Scholar
• Lu C , ZhouQ, YanJ, DuZ, HuangL, LiX. A novel series of tacrine–selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. Eur. J. Med. Chem.62, 745–753 (2013).
   PubMed Web of Science ®Google Scholar
• Xie S-S , WangX, JiangNet al. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. Eur. J. Med. Chem.95, 153–165 (2015).
   PubMed Web of Science ®Google Scholar
• Cooke JP , DzauVJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu. Rev. Med.48, 489–509 (1997).
   PubMed Web of Science ®Google Scholar
• Thatcher GRJ , BennettBM, ReynoldsJN. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res.2, 171–182 (2005).
   PubMedGoogle Scholar
• Fang L , AppenrothD, DeckerMet al. Synthesis and biological evaluation of NO–donor–tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem.51, 713–716 (2008).
   PubMed Web of Science ®Google Scholar
• Chen Y , SunJ, HuangZet al. Design, synthesis and evaluation of tacrine–flurbiprofen–nitrate trihybrids as novel anti-Alzheimer's disease agents. Bioorg. Med. Chem.21, 2462–2470 (2013).
   PubMed Web of Science ®Google Scholar
• De Groot A , KofalviA, WadeMRet al. CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol. Pharmacol.70, 1236–1245 (2006).
   PubMed Web of Science ®Google Scholar
• Wise LE , IredalePA, StokesRJ, LichtmanAH. Combination of rimonabant and donezepil prolongs spatial memory duration. Neuropsychopharmacology32, 1805–1812 (2007).
   PubMed Web of Science ®Google Scholar
• Lange JHM , CoolenHKAC, Van der NeutMAWet al. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism. J. Med. Chem.53, 1338–1346 (2010).
   PubMed Web of Science ®Google Scholar
• Veroff AE , BodickNC, OffenWW, SramekJJ, CutlerNR. Efficacy of xanomeline in Alzheimer's disease: cognitive improvement measured using the computerized neuropsychological test battery (CNTB). Alzheimer Dis. Assoc. Disord.4, 304–312 (1998).
   Google Scholar
• Fang L , JumpertzS, ZhangYet al. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors. J. Med. Chem.53, 2094–2103 (2010).
   PubMed Web of Science ®Google Scholar
• Pang YP , QuiramP, JelacicT, HongF, BrimijoinS. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem.271 (39), 23646–23649 (1996).
   PubMed Web of Science ®Google Scholar
• Fang JH , WangXH, XuZR, JiangFG. Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neurosci.11, 31 (2010).
   PubMed Web of Science ®Google Scholar
• Qian S , HeL, MakM, HanY, HoCY, ZuoZ. Synthesis, biological activity, and biopharmaceutical characterization of tacrine dimers as acetylcholinesterase inhibitors. Int. J. Pharm.477, 442–453 (2014).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML , CavalliA, ValgimigliLet al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem.50, 6446–6449 (2007).
   PubMed Web of Science ®Google Scholar
• Minarini A , MilelliA, TumiattiVet al. Cystamine–tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. Neuropharmacology62, 997–1003 (2012).
   PubMed Web of Science ®Google Scholar
• Fang L , KrausB, LehmannJ, HeilmannJ, ZhangY, DeckerM. Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett.18, 2905–2909 (2008).
   PubMed Web of Science ®Google Scholar
• Chao X , HeX, YangYet al. Design, synthesis and pharmacological evaluation of novel tacrine–caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem. Lett.22, 6498–6502 (2012).
   PubMed Web of Science ®Google Scholar
• Digiacomo M , ChenZ, WangSet al. Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD. Bioorg. Med. Chem. Lett.25, 807–810 (2015).
   PubMed Web of Science ®Google Scholar
• Quintanova C , KeriRS, MarquesSMet al. Design, synthesis and bioevaluation of tacrine–cinnamate-based hybrids as potential bifunctional anti-Alzheimer drug candidates. Med. Chem. Commun.6, 1969–1977 (2015).
   Web of Science ®Google Scholar
• Chen Y , SunJF, FangLet al. Tacrine–ferulic acid–nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J. Med. Chem.55, 4309–4321 (2012).
   PubMed Web of Science ®Google Scholar
• Rosini M , SimoniE, BartoliniMet al. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur. J. Med. Chem.46, 5435–5442 (2011).
   PubMed Web of Science ®Google Scholar
• Wang Y , GuanXL, WuPFet al. Multifunctional mercapto–tacrine derivatives for treatment of age-related neurodegenerative diseases. J. Med. Chem.55, 3588–3592 (2012).
   PubMed Web of Science ®Google Scholar
• Keri RS , QuintanovaC, ChavesS, SilvaDF, CardosoSM, SantosMA. New tacrine hybrids with natural-based cysteine derivatives as multitargeted drugs for potential treatment of Alzheimer's disease. Chem. Biol. Drug Des.87, 101–111 (2016).
   PubMed Web of Science ®Google Scholar
• Quintanova C , KeriRS, ChavesS, SantosMA. Copper(II) complexation of tacrine hybrids with potential anti-neurodegenerative roles. J. Inorg. Biochem.151, 58–66 (2015).
   PubMed Web of Science ®Google Scholar
• Mao F , HuangL. LuoZet al. O-Hydroxyl- or O-amino benzylamine-tacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-b aggregation. Bioorg. Med. Chem.20, 5884–5892 (2012).
   PubMed Web of Science ®Google Scholar
• Fernandez-Bachiller MI , PerezC, CampilloNEet al. Tacrine–melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem.4, 828–841 (2009).
   PubMed Web of Science ®Google Scholar
• Lan JS , XieSS, LiSY, PanLF, WangXB, KongLY. Design, synthesis and evaluation of novel tacrine-(b-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease. Bioorg. Med. Chem.22, 6089–6104 (2014).
   PubMed Web of Science ®Google Scholar
• Skeby KK , SorensenJ, SchiottB. Identification of a common binding mode for imaging agents to amyloid fibrils from molecular dynamics simulations. J. Am. Chem. Soc.135, 15114–15128 (2013).
   PubMed Web of Science ®Google Scholar
• Keri RS , PatilMR, PatilSA, BudagumpiS. A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. Eur. J. Med. Chem.89, 207–251 (2015).
   PubMed Web of Science ®Google Scholar
• Keri RS , QuintanovaC, MarquesSM, CardosoSM, SantosMA. Design, synthesis and neuroprotective evaluation of novel tacrine–benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease. Bioorg. Med. Chem.21, 4559–4569 (2013).
   PubMed Web of Science ®Google Scholar
• Wang Y , WangF, YuJ-Pet al. Novel multipotent phenylthiazole–tacrine hybrids for the inhibition of cholinesterase activity, β-amyloid aggregation and Ca2+ overload. Bioorg. Med. Chem.20, 6513–6522 (2012).
   PubMed Web of Science ®Google Scholar
• Fernandez-Bachiller MI , PerezC, Gonzalez-MunozGCet al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem.53, 4927–4937 (2010).
   PubMed Web of Science ®Google Scholar
• Antequera D , BolosM, SpuchCet al. Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Aβ accumulation and cell death: involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiol Dis.46, 682–691 (2012).
   PubMed Web of Science ®Google Scholar
• Fernandez-Bachiller MI , PerezC, MonjasL, RademannJ, Rodriguez-FrancoMI. New tacrine−4-Oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. J. Med. Chem.55, 1303–1317 (2012).
   PubMed Web of Science ®Google Scholar
• Fylaktakidou KC , Hadjipavlou-LitinaDJ, LitinasKE, NicolaidesDN. Natural and synthetic coumarin derivatives with antiinflammatory/antioxidant activities. Curr. Pharm. Des.10, 3813–3833 (2004).
   PubMed Web of Science ®Google Scholar
• Hamulakova S , JanovecL, HrabinovaMet al. Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors. J. Med. Chem.57, 7073–7084 (2014).
   PubMed Web of Science ®Google Scholar
• Nepovimova E , UliassiE, KorabecnyJet al. Multitarget drug design strategy: quinone−tacrine hybrids designed to block amyloid Aβ aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem.57, 8576–8589 (2014).
   PubMed Web of Science ®Google Scholar
• Li SY , JiangN, XieSS, WangKD, WangXB, KongLY. Design, synthesis and evaluation of novel tacrine–rhein hybrids as multifunctional agents for the treatment of Alzheimer's disease. Org. Biomol. Chem.12, 801–814 (2014).
   PubMed Web of Science ®Google Scholar
• Hui A-l , ChenY, ZhuS-J, GanC-S, PanJ, ZhouA. Design and synthesis of tacrine–phenothiazine hybrids as multitarget drugs for Alzheimer's disease. Med. Chem. Res.23, 3546–3557 (2014).
   Web of Science ®Google Scholar
• O'Leary JC , LiQ, MarinecPet al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener.5, 45–55 (2010).
   PubMed Web of Science ®Google Scholar
• Thiratmatrakul S , YenjaiC, WaiwutPet al. Synthesis, biological evaluation and molecular modeling study of novel tacrineecarbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem.75, 21–30 (2014).
   PubMed Web of Science ®Google Scholar
• Yang W . WongY, NgOTet al. Inhibition of beta-amyloid peptide aggregation by multifunctional carbazole-based fluorophores. Angew. Chem. Int. Ed. Engl.51, 1804–1810 (2012).
   PubMed Web of Science ®Google Scholar
• Sun Y , ChenJ, ChenX, HuangL, LiX. Inhibition of cholinesterase and monoamine oxidase-B activity by tacrine–homoisoflavonoid hybrids. Bioorg. Med. Chem.21, 7406–7417 (2013).
   PubMed Web of Science ®Google Scholar
• Desideri N , BolascoA, FioravantiRet al. Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties. J. Med. Chem.54, 2155–2164 (2011).
   PubMed Web of Science ®Google Scholar
• Chen X , ZengerK, LuppAet al. Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo. J. Med. Chem.55, 5231–5242 (2012).
   PubMed Web of Science ®Google Scholar
• Di Pietro O , Perez-ArealesFJ, Juarez-JimenezJet al. Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting b-amyloid, tau, and cholinesterase pathologies. Eur. J. Med. Chem.84, 107–117 (2014).
   PubMed Web of Science ®Google Scholar
• Cacabelos R . Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics. Neuropsych. Dis. Treat.3, 303–333 (2007).
   PubMedGoogle Scholar
• Simoes MCR , ViegasFPD, MoreiraMSet al. Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease. Mini Rev. Med. Chem.14, 2–19 (2014).
   PubMed Web of Science ®Google Scholar
• Gulcan HO , UnluS, EsiringuIet al. Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorg. Med. Chem.22, 5141–5154 (2014).
   PubMed Web of Science ®Google Scholar
• Omran Z , CaillyT, LescotEet al. Synthesis and biological evaluation as AChE inhibitors of new indanones and thiaindanones related to donepezil. Eur. J. Med. Chem.40, 1222–1245 (2005).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Franco MI , Fernández-BachillerMI, PérezC, CastroA, MartínezA. Design and synthesis of N-benzylpiperidine–purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorg. Med. Chem.13, 6795–6802 (2005).
   PubMed Web of Science ®Google Scholar
• Akrami H , MirjaliliBF, KhoobiMet al. Indolinone-based acetylcholinesterase inhibitors: synthesis, biological activity and molecular modeling. Eur. J. Med. Chem.84, 375–381 (2014).
   PubMed Web of Science ®Google Scholar
• Samadi A , RevengaMF, PérezCet al. Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem.67, 64–74 (2013).
   PubMed Web of Science ®Google Scholar
• Nasica-Labouze J , NguyenPH, SterponeFet al. Amyloid β protein and Alzheimer's disease: when computer simulations complement experimental studies. Chem. Rev.115, 3518–3563 (2015).
   PubMed Web of Science ®Google Scholar
• Wieckowska A , WieckowskiK, BajdaMet al. Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorg. Med. Chem.23, 2445–2457 (2015).
   PubMed Web of Science ®Google Scholar
• Meng F-C , MaoF, ShanW-J, QinF, HuangL, LiX-S. Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents. Bioorg. Med. Chem. Lett.22, 4462–4466 (2012).
   PubMed Web of Science ®Google Scholar
• Zhu Y , XiaoK, MaLet al. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and β-secretase. Bioorg. Med. Chem.17, 1600–1613 (2009).
   PubMedGoogle Scholar
• Bolea I , Juárez-JiménezJ, De Los RíosCet al. Synthesis, biological evaluation and molecular modelling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem.54, 8251–8270 (2011).
   PubMed Web of Science ®Google Scholar
• Bolea I , GellaA, UnzetaM. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J. Neural Transm.120, 893–902 (2013).
   PubMed Web of Science ®Google Scholar
• Rizzo S , TarozziA, BartoliniMet al. 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. Eur. J. Med. Chem.58, 519–532 (2012).
   PubMed Web of Science ®Google Scholar
• Huang L , MiaoH, SunY, MengF, LiX. Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease. Eur. J. Med. Chem.87, 429–439 (2014).
   PubMed Web of Science ®Google Scholar
• Ynet News . Israeli researcher discovers Alzheimer's drug by accident. www.ynetnews.com/articles/0,7340,L-4498541,00.html.
   Google Scholar
• Bailey JA , LahiriDK. A novel effect of rivastigmine on presynaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J. Neurochem.112, 843–853 (2010).
   PubMed Web of Science ®Google Scholar
• Camps P , Munoz-TorreroD. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev. Med. Chem.2, 11–25 (2002).
   PubMed Web of Science ®Google Scholar
• Mustazza C , BorioniA, RosariMet al. Synthesis and cholinesterase activity of phenylcarbamates related to rivastigmine, a therapeutic agent for Alzheimer's disease. Eur. J. Med. Chem.37, 91–109 (2002).
   PubMed Web of Science ®Google Scholar
• Sterling J , HerzigY, GorenTet al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem.45, 5260–5279 (2002).
   PubMed Web of Science ®Google Scholar
• Toda N , TagoK, MarumotoSet al. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem.11, 4389–4415 (2003).
   PubMed Web of Science ®Google Scholar
• Greig NH , SambamurtiK, YuQS, BrossiA, BruinsmaGB, LahiriDK. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res.2, 281–290 (2005).
   PubMedGoogle Scholar
• Shinada M , NarumiF, OsadaYet al. Synthesis of phenserine analogues and evaluation of their cholinesterase inhibitory activities. Bioorg. Med. Chem.20, 4901–4914 (2012).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML , BartoliniM, CavalliAet al. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J. Med. Chem.47, 5945–5952 (2004).
   PubMed Web of Science ®Google Scholar
• Heinrich M , TeohHL. Galanthamine from snowdrop – the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J. Ethnopharmacol.92, 147–162 (2004).
   PubMed Web of Science ®Google Scholar
• Irwin RL , SmithHJ. Cholinesterase inhibition by galanthamine and lycoramine. Biochem. Pharmacol.3, 147–148 (1960).
   PubMed Web of Science ®Google Scholar
• Mary A , RenkoDZ, GuillouC, ThalC. Potent acetylcholinesterase inhibitors: design, synthesis, and structureactivity relationships of bis-interacting ligands in the galanthamine series. Bioorg. Med. Chem.6, 1835–1850 (1998).
   PubMed Web of Science ®Google Scholar
• Guillou C , MaryA, RenkoDZ, GrasE, ThalC. Potent acetylcholinesterase inhibitors: design, synthesis and structureactivity relationships of alkylene linked bis–galanthamine and galanthamine–galanthaminium salts. Bioorg. Med. Chem. Lett.10, 637–639 (2000).
   PubMed Web of Science ®Google Scholar
• Jia P , ShengR, ZhangJet al. Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors. Eur. J. Med. Chem.44, 772–784 (2009).
   PubMed Web of Science ®Google Scholar
• Vezenkov L , SevalleJ, DanalevDet al. Galanthamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and γ-secretase inhibition activities. Curr. Alzheimer. Res.9, 600–605 (2012).
   PubMed Web of Science ®Google Scholar
• Rao VK , RaoAJ, ReddySS, RajuCN, RaoPV, GhoshSK. Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine. Eur. J. Med. Chem.45, 203–209 (2010).
   PubMed Web of Science ®Google Scholar
• Maa X , TanaC, ZhuaD, GangDR, XiaoP. Huperzine A from Huperzia species – an ethnopharmacolgical review. J. Ethnopharmacol.113, 15–34 (2007).
   PubMed Web of Science ®Google Scholar
• Wang R , YanH, TangX-C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin.27, 1–26 (2006).
   PubMed Web of Science ®Google Scholar
• Guo B , XuL, WeiY, LiuC. Research advances of Huperzia serrata (Thunb.) Trev. Zhongguo Zhong Yao Za Zhi34, 2018–2023 (2009).
   PubMedGoogle Scholar
• Raves ML , HarelM, PangYP, SilmanI, KozikowskiAP, SussmanJL. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol.4, 57–63 (1997).
   PubMedGoogle Scholar
• Zhang HY , TangXC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol. Sci.27, 619–625 (2006).
   PubMed Web of Science ®Google Scholar
• Lallement G , BailleV, BaubichonDet al. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology23, 1–5 (2002).
   PubMed Web of Science ®Google Scholar
• McKinney M , MillerJH, YamadaF, TuckmantelW, KozikowskiAP. Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur. J. Pharmacol.203, 303–305 (1991).
   PubMed Web of Science ®Google Scholar
• Tang XC , KindelGH, KozikowskiAP, HaninI. Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo. J. Ethnopharmacol.44, 147–155 (1994).
   PubMed Web of Science ®Google Scholar
• Liu J , ZhangH-Y, WangLM, TangXC. Inhibitory effects of huperzine B on cholinesterase activity in mice. Zhongguo Yao Li Xue Bao20, 141–145 (1999).
   PubMed Web of Science ®Google Scholar
• Kozikowski AP , MillerCP, YamadaFet al. Delineating the pharmacophoric elements of huperzine A importance of the unsaturated three-carbon bridge to its AChE inhibitory activity. J. Med. Chem.34, 3399–3405 (1991).
   PubMed Web of Science ®Google Scholar
• Carlier PR , DuDM, HanF-Yet al. Dimerization of inactive fragment of huperzine A produces drug with twice the potency of the natural product. Angew. Chem. Int. Ed. Engl.39, 1775–1777 (2000).
   PubMed Web of Science ®Google Scholar
• Kozikowski AP , CampianiG, SunLQ, WangS, SaxenaA, DoctorBP. Identification of a more potent analogue of the naturally occurring alkaloid huperzine A. predictive molecular modeling of its interaction with AChE. J. Am. Chem. Soc.118, 11357–11362 (1996).
   Web of Science ®Google Scholar
• Kozikowski AP , PrakashKRC, SaxenaA, DoctorBP. Synthesis and biological activity of an optically pure 10-spirocyclopropyl analog of huperzine A. Chem. Commun.1287–1288 (1998).
   Web of Science ®Google Scholar
• Xiong ZQ , TangXC, LinJL, ZhuDY. Effects of isovanihuperzine A on cholinesterase and scopolamine-induced memory impairment. Acta Pharmacol. Sin.16, 21–25 (1995).
   Web of Science ®Google Scholar
• Ma X , GangDR. The lycopodium alkaloids. Nat. Prod. Rep.21, 752–772 (2004).
   PubMed Web of Science ®Google Scholar
• Kozikowski AP , WernerT. US1998018260 (1999).
   Google Scholar
• Shao D , ZouC, LuoC, TangX, LiY. Synthesis and evaluation of tacrine–E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett.14, 4639–4642 (2004).
   PubMed Web of Science ®Google Scholar
• Alonso D , DorronsoroI, RubioLet al. Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg. Med. Chem.13, 6588–6597 (2005).
   PubMed Web of Science ®Google Scholar
• Camps P , FormosaaX, GaldeanoaCet al. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chem. Biol. Interact.187, 411–417 (2010).
   PubMed Web of Science ®Google Scholar
• Galdeano C , ViaynaE, SolaIet al. Huprine−tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and Prion diseases. J. Med. Chem.55, 661–669 (2012).
   PubMed Web of Science ®Google Scholar
• Zheng H , YoudimMBH, FridkinM. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective–neurorestorative moieties for alzheimer's therapy. J. Med. Chem.52, 4095–4098 (2009).
   PubMed Web of Science ®Google Scholar
• Amit T , Avramovich-TiroshY, YoudimMB, MandelS. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J.22, 1296–1305 (2008).
   PubMed Web of Science ®Google Scholar
• Gal S , ZhengH, FridkinM, YoudimMB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem.95, 79–88 (2005).
   PubMed Web of Science ®Google Scholar
• Zheng H , GalS, WeinerLMet al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem.95, 68–78 (2005).
   PubMed Web of Science ®Google Scholar
• Sheng R , LinX, LiJ, JiangY, ShangZ, HuY. Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett.15, 3834–3837 (2005).
   PubMedGoogle Scholar
• Viayna E , GomezT, GaldeanoCet al. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates. Chem. Med. Chem.5, 1855–1870 (2010).
   Google Scholar
• Weinstock M , BejarC, WangRH. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Trans. Suppl.60, 157–169 (2000).
   PubMedGoogle Scholar